27 drugs have been successfully renewed, 5 of which are Chinese patent medicines!

[industry trends of pharmaceutical network] in 2019, the negotiation of medical insurance has come to an end In addition to the success of the negotiation of 70 new varieties, there are 27 successful "renewal" of drugs, including 22 varieties of Western medicine and 5 varieties of Chinese patent medicine The Chinese patent medicines under negotiation include ginkgolide glucosamine injection, ginkgolide injection, compound Huangdai tablet, astragalus polysaccharide for injection and Shenyi capsule The industry believes that entering the medical insurance means exchanging price for quantity Judging from the situation that these Chinese patent medicines are willing to reduce prices, there is a strong willingness to enter the medical insurance of traditional Chinese medicine Ginkgolide injection: the production enterprise of ginkgolide injection is Chengdu Baiyu pharmaceutical It is reported that since the ginkgolide injection entered the national medical insurance catalog in 2017, the market demand is increasing rapidly In the first quarter of 2019, the market demand of Baiyu pharmaceutical has reached 2 million, more than 30% of the annual sales in 2017 The bid price of ginkgolide injection (specification: 2ml) of Chengdu Baiyu Pharmaceutical Co., Ltd entering the category B directory of medical insurance is 130.08 yuan The price of this variety decreased by 84.87% and 19.68 yuan It is worth mentioning that in March this year, Chengdu Baiyu pharmaceutical's ginkgolide injection production base officially started construction, with a total investment of 3.3 billion It is expected to be completed and put into operation in June 2019 After being put into production, it is expected to achieve several billion pieces of annual production, and the company is expected to exceed 6 billion yuan in annual sales in the future Ginkgo diterpenoid lactone and meglumine injection: the production enterprise of Ginkgo diterpenoid lactone and meglumine injection is Kangyuan pharmaceutical The data shows that the operating revenue of Kongyuan pharmaceutical's ginkgolide and meglumine injection in 2016 was 75.8466 million yuan, accounting for 2.53% of the company's total operating revenue In 2017, the national negotiation of Ginkgo diterpenoid lactone and meglumine injection of Kangyuan pharmaceutical entered the category B Medical Insurance catalogue, and the price decreased from about 620 yuan to 316 yuan / piece According to the company's 2018 annual report, the sales volume of Ginkgo diterpenoid lactone reached 1577500 boxes in 2018, with an increase of 66.39%, and the sales volume was about 500 million yuan This time, the price of Ginkgo diterpenoid lactone glucosamine injection (specification: 5ml) of Kangyuan Pharmaceutical Co., Ltd decreased by 70.35%, and the payment standard of medical insurance was 93.7 yuan The industry believes that although the price reduction is large, due to the large scale of the overall market, ginkgo diterpenoid lactone meglumine injection is expected to grow rapidly after entering the medical insurance Compound Huangdai tablet: the production enterprise of compound Huangdai tablet is Yifan pharmaceutical, a subsidiary of Yifan pharmaceutical Compound Huangdai tablet was used for the initial treatment of acute promyelocytic leukemia, and it was entered into the medical insurance through medical insurance negotiation in 2017 In May 2018, Yifan pharmaceutical once revealed that since the compound Huangdai tablet was included in the national medical insurance negotiation catalog, it has provided a new growth point for the company's business performance improvement, and its sales volume in the first quarter of 2018 increased by more than 60% compared with the same period last year The bid price of the compound Huangdai tablet (specification: 0.27g) of Yifan medicine for medical insurance is 10.5 yuan The price reduction is 2.95% and 10.19 yuan this time Shenyi capsule: the production enterprise of Shenyi capsule decreased by 7.07% to Jilin Yatai, which entered the medical insurance in 2000 The company once replied in the investor's question that after Shenyi capsule entered the national medical insurance, according to relevant policies, in 2018, the company completed the catalog supplement of blank provinces and the adjustment of key market layout, and completed the overall marketing strategic deployment in combination with the industry policies issued in the year The bid price of Shenyi capsule is 6.65 yuan The decrease was 7.07% and the price was 6.18 yuan The company said that Shenyi capsule was included in the national medical insurance catalog, further expanding the sales channels of the pharmaceutical industry, improving the sales layout, and benefiting the scale release of the company's pharmaceutical products Scutellaria polysaccharide for injection: the decrease rate is 61.30% The production enterprise of Scutellaria polysaccharide for injection is Tianjin sanuo pharmaceutical, which entered the medical insurance in 2004 According to the data, the market scale of APS for injection was 113 million yuan in 2015, a year-on-year decrease of 13.57% The bid price of Scutellaria baicalensis polysaccharide for injection (specification: 250mg) was 517.19 yuan, with a decrease of 61.30% and a price of 200 yuan.